ArticleCancer science2021

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.

Shunji Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.